Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Condition: Melanoma Intervention: Drug: Fluzoparib Camrelizumab Temozolomide Sponsor: Peking University Cancer Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
Condition: BRAF Positive Metastatic Melanoma Intervention: Sponsor: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System
Conditions: Meningeal Melanocytoma; Meningeal Melanomatosis; Meningeal Melanocytosis; Meningeal Melanoma Intervention: Sponsor: Central Hospital, Nancy, France Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Condition: Melanoma Intervention: Drug: Fluzoparib Camrelizumab Temozolomide Sponsor: Peking University Cancer Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
Condition: BRAF Positive Metastatic Melanoma Intervention: Sponsor: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System
Conditions: Meningeal Melanocytoma; Meningeal Melanomatosis; Meningeal Melanocytosis; Meningeal Melanoma Intervention: Sponsor: Central Hospital, Nancy, France Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Condition: Melanoma Intervention: Drug: Fluzoparib Camrelizumab Temozolomide Sponsor: Peking University Cancer Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
Condition: BRAF Positive Metastatic Melanoma Intervention: Sponsor: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System
Conditions: Meningeal Melanocytoma; Meningeal Melanomatosis; Meningeal Melanocytosis; Meningeal Melanoma Intervention: Sponsor: Central Hospital, Nancy, France Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Condition: Melanoma Intervention: Drug: Fluzoparib Camrelizumab Temozolomide Sponsor: Peking University Cancer Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
Condition: BRAF Positive Metastatic Melanoma Intervention: Sponsor: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System
Conditions: Meningeal Melanocytoma; Meningeal Melanomatosis; Meningeal Melanocytosis; Meningeal Melanoma Intervention: Sponsor: Central Hospital, Nancy, France Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Condition: Melanoma Intervention: Drug: Fluzoparib Camrelizumab Temozolomide Sponsor: Peking University Cancer Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Conditions: Head and Neck Cancer; Cervical Cancer; Non-small Cell Carcinoma; Melanoma; Ovarian Cancer; Anogenital Cancers; HPV - Anogenital Human Papilloma Virus Infection; HPV-Related Cervical Carcinoma; HPV-Related Carcinoma; HPV-Related Squamous Cell Carcino ma; HPV-Related Malignancy; HPV-Related Adenocarcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; HPV-Related Adenosquamous Carcinoma; HPV-Associated Vaginal Adenocarcinoma; HPV-Related Endocervical Adenocarcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Ve...
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
